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Abstract
KITENIN promotes invasion of mouse colon adenocarcinoma
(CT-26) cells in vivo . Here, we studied the effects of in vivo
KITENIN ablation on established tumors by using pSUPER
vectors (pSUPER-KITENIN) producing short interfering RNA
(siRNA). When pSUPER-KITENIN was given weekly or semi-
weekly for 1 month into tail vein of syngeneic mice that have
established colon tumors, tumor size regressed markedly and
metastases were inhibited. In mice injected with pSUPER-
KITENIN, serum interleukin-2 (IL-2) and IFN-; increased and
CD4+ and CD8+ T cells infiltrated in the regressed tumor
tissues. These effects, observed beginning 2 days after i.v.
injection, imply that immune response is involved in the
antitumor action of pSUPER-KITENIN. Using a yeast two-
hybrid assay, we identified two KITENIN-interacting proteins
for the possible mediators of these actions: 90K protein, a
known immune modulatory glycoprotein, and protein kinase
C inhibitor (PKCI). 90K was increased in the culture medium
from CT-26/antisense KITENIN/90K cells. Double culture of
accessory cells with CT-26/antisense KITENIN/90K cells
revealed increased secretion of IL-1 and IL-6. Overexpression
of 90K in CT-26/antisense KITENIN cells further delayed
tumor growth compared with that of CT-26/antisense KITE-
NIN cells. Actin arrangement was distorted in CT-26/antisense
KITENIN and CT-26/antisense PKCI cells, whereas overexpres-
sion of PKCI resulted in increased invasiveness to fibronectin.
Thus, antitumor effects of KITENIN siRNA derives from both
the generation of a tumor-specific immune response in vivo
through increased 90K secretion from tumor cells and the
suppression of tumor invasion in which PKCI is related to
increased invasiveness. Moreover, siRNA targeting of KITENIN
can function as a chemotherapeutic strategy against colon
cancer. (Cancer Res 2005; 65(19): 8993-9003)
Introduction
Most tumor cells are poorly immunogenic and do not elicit an
immune response sufficient for elimination of the tumor.
Alternatively, the failure of the immune system to recognize and
react to tumor antigens may be due to improper antigen
presentation or insufficient costimulation (1). Certain cytokines,
when administered systemically or locally, can lead to successful
immune recognition of the tumor and mobilization of an effective
immune response. Thus, cytokine-engineered nonimmunogenic
tumor cells can elicit a strong tumor-specific immune response. In
addition, tumor cells produce and secrete proteins that can directly
affect the host immune response to the tumor, either positively or
negatively (2, 3).
90K, a tumor-associated protein with possible immunoregulatory
properties in CG-5 human breast cancer cells, is detected in the sera
of normal as well as tumor-bearing patients (4, 5). The 90K protein
belongs to the scavenger receptor cysteine-rich domain superfamily
of proteins implicated in immune defense and immunoregulation
(6). This protein has been shown to enhance the in vitro generation
of cytotoxic effector cells from peripheral blood mononuclear cells
(PBMC) and to indirectly enhance interleukin-2 (IL-2) production
by PBMC and suggested to activate an early step in the immune
response to tumors, resulting in amore effective antitumor response
(7–10).
Recently, we cloned KITENIN (KAI1 COOH-terminal interacting
tetraspanin), a member of the tetraspanin protein family, which
interacted specifically with the COOH-terminal cytoplasmic
domain of KAI1 (11). We found that, compared with parental cells,
KITENIN-overexpressing CT-26 mouse colon cancer cells showed
greater tumorigenicity and early hepatic metastasis in vivo as well
as greater invasiveness and adhesion to fibronectin in vitro . There
was a positive correlation between the expression of KITENIN and
the presence of distant metastasis, indicating that KITENIN can
function as a metastasis-promoting gene. Our previous results
suggest that an antisense KITENIN strategy may be able to inhibit
metastasis in colon cancers (11).
Synthetic short interfering RNA (siRNA), known as RNA
interference, is a powerful tool to induce strong and specific
suppression of gene expression (12). However, this reduction in
gene expression is transient, which severely restricts its applica-
tions. Recently, a new expression vector system, pSUPER (suppres-
sion of endogenous RNA) was developed that directs the synthesis
of siRNA-like transcripts in mammalian cells (13). The siRNA
expression mediated by this vector causes efficient and specific
down-regulation of gene expression, resulting in functional
inactivation of targeted genes.
Thus, in this study, we used the pSUPER vector system to deliver
KITENIN siRNA for the efficient and stable suppression of
KITENIN expression in the established tumors of syngeneic mice.
Surprisingly, we observed marked inhibition of the growth of
established tumors as well as suppression of distant metastases
of colon cancer following four weekly or semiweekly i.v. injections
of pSUPER-KITENIN. In addition, we characterized the effect of
antisense KITENIN and two of its interacting proteins, 90K and
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protein kinase C inhibitor (PKCI) proteins, both in vitro and in vivo .
Here, we provide in vitro and in vivo evidences showing that
antitumor effects of KITENIN siRNA on established colon tumors
derives from both the generation of a tumor-specific immune
response in vivo through increased 90K protein secretion from
nonimmune tumor cells and the suppression of tumor invasion in
which PKCI is related to increased invasiveness as well as helping
the KAI1’s suppressive action. The present study suggests that
siRNA targeting the KITENIN could be useful in the treatment of
colon cancer, together with other chemotherapeutic agents.
Materials and Methods
Yeast two-hybrid assay. To identify the protein interacting with
KITENIN, full-length KITENIN cDNA was used as bait. The yeast reporter
strain AH109 was sequentially transformed with pGBKT7-KITENIN and
pGADT7-mouse testis cDNA library. Positive clones were selected and
prepared as previously described (11). The positive clone was identified by
sequencing.
Constructs of KITENIN short interfering RNA and cDNA. For
silencing the expression of KITENIN, five regions of human and mouse
KITENIN were targeted for siRNA. Two of the five regions were shown
to specifically reduce the expression of human KITENIN (KIT-siRNA 2,
5V-ACGCTACCTGGGCCTCACC-3V; KIT-siRNA 5, 5V-AGAAGCGGAAAGCAA-
GGCT-3V). In mice, the two identical regions (KIT-siRNA 2, 5V-GCGCTAT-
CTGGGCCTTACC-3V; KIT-siRNA 5, 5V-AGAAGCGGAGAGCAAGACT-3V) were
selected and constructed in the pSUPER vector (OligoEngine, Seattle, WA).
To generate siRNAs, equimolar amounts of complementary sense and
antisense strands were mixed and annealed each in a 50-AL reaction at
90jC for 4 minutes, 70jC for 10 minutes, 60jC for 30 minutes, 37jC for
20 minutes, and 25jC for 10 minutes. The pSUPER vector was digested
with BglII and HindIII, and the annealed oligos were ligated into the vector.
The NH2-terminal half of full-length KITENIN cDNA (antisense KITENIN
cDNA) was inserted inversely into the mammalian expression vector
pREP4 (Invitrogen, Carlsbad, CA).
Cell culture and transfection. CT-26 cells, human colon cancer
(KM1214) cells, human embryonic kidney (293) cells, and mouse accessory
(RAW 264.7) cells were grown in DMEM supplemented with 10% fetal
bovine serum (FBS). Transfection was done using FuGENE 6 (Roche,
Indianapolis, IN) as described (14). The KITENIN cDNA, antisense KITENIN
cDNA, antisense PKCI cDNA, or 90K cDNA was transfected into CT-26/
parent cells (CT-26/KITENIN, CT-26/antisense KITENIN, CT-26/antisense
PKCI, and CT-26/90K cells). Antibiotic-resistant cells were selected and
maintained by culture with G418 (500 Ag/mL), zeocin (200 Ag/mL,
Invitrogen), and/or hygromycin (100 Ag/mL, Clontech, Palo Alto, CA).
Two weeks later, surviving clones were analyzed by Western blot for
expression of the respective protein.
Staining of filamentous actin. CT-26/antisense KITENIN or CT-26/
antisense PKCI cells were seeded onto an eight-well Lab-Tek Chamber Slide
Glass (Nunc, Scotts Valley, CA) and were grown in DMEM supplemented
with 10% FBS. Cells were washed thrice with PBS (pH 7.4) and fixed in 3.7%
formaldehyde solution in PBS for 10 minutes at room temperature. After
washing with PBS and placing with 0.1% Triton X-100 in PBS for 5 minutes,
the cells were incubated with Alexa fluor 488 phalloidin (A12379, Molecular
Probes, Eugene, OR) for 30 minutes at room temperature and then washed
thrice with PBS buffer. The cells were mounted using Prolong Gold (P36939,
Molecular Probes) and examined with a Laser Scanning Confocal
Microscope (Leica Microscope Systems, Wetzlar, Germany).
In vivo tumor growth. Prior approval of the experimental protocol was
obtained from the Chonnam National University Medical School Research
Institutional Animal Care and Use Committee. Maintenance of animals and
all in vivo experiments were done according to The Guiding Principles in
the Care and Use of Animals (DHEW publication, NIH 80-23). CT-26 cells
(1  106 cells per mouse) were injected s.c. into BALB/c syngeneic mice.
The mice received tail vein injections of vector or KITENIN siRNA with
FuGENE 6 at 1 or 2 weeks after CT-26 injection, and the injection interval
was 1 week. The pSUPER-KITENIN was the mixture of KITENIN S2 and S5
administered at 100 Ag doses in f100 AL per injection in each mouse as
described (15). Tumor size and volume were measured daily from the first
to the fifth week as previously described (14). At the fifth week after
injection, the presence of metastasis in the liver and lung tissues of each
group was evaluated by gross and microscopic examination.
Production of anti-protein kinase C inhibitor antibody. We prepared
the GST-PKCI fusion construct by subcloning the full-length of PKCI into
the unique EcoRI and XhoI sites of pGEX-4T as described (14). Rabbit
polyclonal antiserum recognizing PKCI was prepared using the GST-PKCI
fusion protein. The serum was filtered through a column of GST-PKCI
fusion protein, and the column was eluted with a low-pH buffer. It was then
filtered through a column of glutathione S-transferase (GST) protein to
remove the anti-GST component.
In vitro translation. To verify the interactions with KITENIN identified
in the yeast two-hybrid screen, in vitro transcription and translation was
done using the TNT Coupled Reticulocyte Lysate System (Promega,
Madison, WI). Translations were synthesized in vitro by T7 RNA polymerase
promoter and rabbit reticulocyte lysate. Circular plasmid DNA (1 Ag)
is added directly to TNT lysate, TNT T7 RNA polymerase, amino acid
mixture (Leu/Met), and RNasin, and incubated in a 50-AL reaction for
90 minutes at 30jC.
Immunoprecipitation. Proteins of indicated cells were prepared as
described (11), incubated with anti-KITENIN or anti-V5 antibody and
protein A/G-agarose beads (Pierce, Rockford, IL), and then were analyzed
by blotting with anti-PKCI or anti-KITENIN polyclonal antibody.
Western blot analysis. Transfer of proteins and immunoblotting were
done as described (14). The blot was reprobed with anti-actin antibody
(I-19, Santa Cruz Biotechnology, Santa Cruz, CA) to control for loading.
Cell invasion assay. Cell migration was measured using the Transwell
migration apparatus (Costar, Inc., Cambridge, United Kingdom) as
described (14).
Purifying 90K protein from culture supernatant. Culturemediumwas
harvested from CT-26/90K/antisense KITENIN cells between 24 and 48 hours
after seeding, and cell culture supernatant (150mL) was applied onto Ni-NTA
spin columns (Qiagen, Valencia, CA) equilibrated with buffer [20 mmol/L
Tris-HCl (pH 7.5), 150 mmol/L NaCl, 2 mmol/L CaCl2, 20 mmol/L imidazole].
The absorbed proteins were eluted with 2  750 AL buffer containing
200 mmol/L imidazole. Eluants were combined and dialyzed against buffer
[5 mmol/L Tris-HCl (pH 7.5), 10 mmol/L NaCl, 0.2 mmol/L CaCl2] overnight.
Aliquots (15 AL) were separated by SDS-PAGE under reducing conditions and
confirmed by immunoblotting.
ELISA. ELISA was used to quantify cytokines in mouse serum and cell
lines after KITENIN siRNA treatment. For collecting mouse serum, vector or
KITENIN siRNA was injected at 1 week after the injection of CT-26 cell in
BALB/C mice. The blood of each group (n = 6) was collected everyday for
6 days. IL-1h, IL-2, IL-4, IL-5, IL-6, and IFN-g were measured as
recommended (R&D Systems, Minneapolis, MN).
In RAW 264.7 cells, the change of cytokine secretion by the effect of
overexpressed 90K was measured. CT-26/parent, CT-26/90K, and CT-26/
90K/antisense KITENIN cells (2  105) were cultured in the lower chamber
of the Transwell, and RAW cells (1  105) were cultured in the upper
chamber. After 2 days, the supernatant was centrifuged and was measured
for IL-1h, IL-2, IL-4, IL-5, IL-6, and IFN-g. In addition, the cultured medium
was harvested from RAW cells at 24 hours after adding purified 90K protein
derived from supernatant of CT-26/90K/antisense KITENIN cells, and IL-1
and IL-6 were measured by ELISA.
Histochemistry. KITENIN siRNA S2 or S5 (100 Ag) was injected i.v.
(n = 4), and internal organs (liver, lung, kidney, and spleen) were excised for
histochemistry at 3 days after injection. The tissue sections were
deparaffinized, rehydrated, and rinsed. Distribution of green fluorescent
protein in mouse tissue, expressed by pSUPER KITENIN siRNA, was
examined immediately by fluorescent microscope.
We prepared other groups of syngeneic mice, which were injected s.c.
with CT-26/parent, CT-26/90K, or CT-26/antisense KITENIN/90K cells
(n = 12 for each group). Two weeks after injection, liver and lung were
excised weekly in each experimental group (n = 3) for histochemistry up to
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5 weeks. The tissue sections were deparaffinized, rehydrated, and stained
with H&E for examining metastatic cells with light microscope.
Reverse transcription-PCR. Reverse transcription was done as
described (14). The reverse transcription-PCR (RT-PCR) exponential phase
was determined to be 30 cycles to allow quantitative comparison of each
cDNA from identical reactions. All reactions involved an initial denaturation
at 94jC for 5 minutes followed by 30 cycles at 94jC for 1 minute, 60jC for
1 minute, and at 72jC for 2 minutes using PCR primers ( for KITENIN, sense,
5V-GGAATTCCATTCGAAAAAATCTA-3V; antisense, 5V-CCGCTCGAGGCC-
CAGGTAGCGTTTGCA-3V; for 90K, sense, 5V-CTACCAGTCCTTCCAGACT-3V;
antisense, 5V-AGCATCAGGGCTTTGTTTTCGTAG-3V).
Statistical analysis. Results are expressed as mean F SE. Experimental
differences were tested for statistical significance using ANOVA and
Student’s t test. All statistical tests were two sided, and Ps < 0.05 were
considered statistically significant.
Results
Expression of KITENIN short interfering RNA using pSUPER
vector induces KITENIN mRNA degradation. We designed five
synthetic siRNA oligonucleotides targeted against different sequen-
ces of human KITENIN (Table 1), subcloned each of them into
pSUPER vector, and compared their ability to inhibit KITENIN
expression in a transient transfection experiment using 293
(Fig. 1A, top) and KM1214 (Fig. 1A, bottom) cells. Two KITENIN
siRNAs (human pSUPER-KITENIN S2, S5) were identified that
reduced both mRNA (data not shown) and protein levels (Fig. 1A).
This suppressant effect of KITENIN siRNA was greater in 293 cells
than KM1214 cells. In addition, effective silencing of KITENIN
expression was observed when S2 and S5 KITENIN siRNAs (mouse
pSUPER-KITENIN S2, S5) designed to the murine KITENIN were
stably transfected into CT-26 cells (Fig. 1B). KITENIN siRNA
S2–transfected KM1214 cells showed significantly decreased
in vitro motility and invasive potential by fibronectin compared
with parent cells (data not shown).
To show the ability of pSUPER-KITENIN (siRNA) to suppress
KITENIN expression in vivo , siRNAs were given to BALB/c mice, a
syngeneic host of CT-26 cells, through tail vein with amounts of
100 Ag in 200 AL volume. Biodistribution of siRNAs was assessed by
observing the green fluorescent protein in tissue samples from
liver, lung, and spleen obtained at 72 hours after injection. A
substantial amount of fluorescence was observed in these tissues,
and marked fluorescent expression was also found around blood
vessels, indicating that a high amount was transfected into
endothelial cells (Fig. 1C). In vivo KITENIN expression was
examined by RT-PCR and Western blot analyses in the liver, lung,
spleen, and kidney at 3 days, 1, 2, 3, and 4 weeks after i.v. siRNA
injection. Expression of KITENIN decreased 3 days after injection.
Potent inhibition of KITENIN mRNA expression was observed
at 1 week and peaked at 2 weeks, especially in lung and liver.
KITENIN mRNA expression recovered to control level after 3 weeks
(Fig. 1D). However, the suppression of KITENIN proteins were
observed from 3 days after injection and persisted until 3 weeks
(Fig. 1E). These results indicate that the silencing effect of single
siRNA injection on the KITENIN expression in various tissues
persists for 2 weeks and suggests that the effect of KITENIN siRNA
could be maintained if given i.v. at weekly intervals.
Targeted suppression of KITENIN expression via intrave-
nous KITENIN short interfering RNA injection renders mice
resistant to tumor challenge. To examine whether i.v. adminis-
tration of KITENIN siRNA affects progression of experimental
colon cancer, 50 Ag of both KITENIN siRNA S2 and S5 mixed with
FuGENE 6 were given i.v. into the tail vein of syngeneic mice at
1 week before, simultaneously, and 1 week after the injection of CT-
26 cells. KITENIN siRNA was given weekly for 1 month. After a
single injection, tumor necrosis was observed beginning 2 days, but
new tumor mass had grown around the necrotic tumor tissues
after 4 days. However, the tumor size was substantially regressed in
the KITENIN siRNA injection group compared with the control
vector group, regardless of injection timing (Fig. 2A). Interestingly,
normal tumor growth was observed during 2 weeks after injection
of CT-26 cells in mice in which i.v. siRNA delivery was started 1
week before the tumor challenge. However, substantial tumor
regression was observed after the fourth injection, which was given
at 2 weeks after the tumor challenge. Remarkably, complete
regression of established tumor after four deliveries of KITENIN
siRNA was observed in one mouse, starting at 1 week after the
injection of CT-26 cells.
Next, to mimic the clinical situation, we observed whether i.v.
siRNA injection affects tumor growth and metastasis of exper-
imental colon cancer after the tumor is already formed. KITENIN
siRNA was given weekly five times starting at 1 or 2 weeks after
the injection of CT-26 cells. The administration of KITENIN
siRNA substantially delayed the growth of established tumor in
all mice in comparison with control vector–injected group,
especially after 1 month of tumor cell injection (Fig. 2B). The
results were similar between both injection groups, despite the
difference in how soon the injections started after tumor
formation. After 1 month, regression of the established tumor
was observed in all mice, and 10 of 13 mice survived at 56 days
in the KITENIN siRNA group. In the vector group, the tumor
grew quickly after 1 month, and no regression of tumors was
observed. Only 5 of 20 mice survived at 56 days in the vector
group (Fig. 2C). Thus, KITENIN siRNA delivery significantly
prolonged the survival of mice more than the vector alone (77 F
12.2 versus 25 F 9.9 days, P < 0.01). Internal organs were
examined by H&E staining for metastases of adenocarcinoma
cells in the mice receiving KITENIN siRNA or vector (n = 13
versus n = 20). After 6 weeks, liver and lung metastases were
detected in all control mice (Fig. 2D, top columns), whereas liver
or lung was still intact in the mice (n = 12) with KITENIN siRNA
(Fig. 2D, bottom columns). In one mouse that received KITENIN
siRNA, some liver metastasis was detected, but metastatic focus
was very small compared with those of vector group. Thus, the
metastasis to liver or lung was inhibited in the KITENIN siRNA-
delivered mice compared with vector group. These results suggest
that in vivo inhibition of KITENIN expression renders mice
resistant to tumor challenge.
Table 1. KITENIN-siRNA sequences
Species Name Sequence (19 mer)
Human KIT-siRNA 1 5V-GCTGACATGCCACGGGTGT-3V
KIT-siRNA 2 5V-ACGCTACCTGGGCCTCACC-3V
KIT-siRNA 3 5V-GGAGGGATGAGCTGGAGCC-3V
KIT-siRNA 4 5V-GGTTGCAGTGGAAGAGGCC-3V
KIT-siRNA 5 5V-AGAAGCGGAAAGCAAGGCT-3V
Mouse KIT-siRNA 1 5V-GCGGATGTGCCGCGGGTGT-3V
KIT-siRNA 2 5V-GCGCTATCTGGGCCTTACC-3V
KIT-siRNA 3 5V-GGAGGGAGGAGCTGAAACC-3V
KIT-siRNA 4 5V-AGTGGCTGTGGAGGAAGCC-3V
KIT-siRNA 5 5V-AGAAGCGGAGAGCAAGACT-3V
Antitumor Effects of KITENIN siRNA
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Intravenous injection of KITENIN short interfering RNA
into syngeneic mice allows the generation of a tumor-specific
immune response in vivo. The necrosis of established tumors
observed beginning 2 days after a single i.v. KITENIN siRNA
injection prompted us to investigate whether resistance to tumor
challenge induced by selective KITENIN blockade could be
associated with an enhancement of immune response in vivo . For
analyzing cytokine production and T-cell accumulation, we
obtained serum and tumor tissue daily for 6 days from mice given
single injection of KITENIN siRNA or control vector given at 10 days
after CT-26 cell challenge. At first, we examined the duration of
tumor regression effect after single injection. The part of tumor
tissue was black colored at 1 day after i.v. KITENIN siRNA (Fig. 3A,
top first column). At 2 days after injection, tumor size was decreased,
and crust formation was observed (Fig. 3A, top second column).
These effects seemed to persist until 3 to 4 days after single
injection, then tumor growth started again after 5 days (Fig. 3A,
top fifth column). However, injection of vector alone did not affect
the progression of the established tumor (Fig. 3A, bottom columns).
We measured tumor volume and then amounts of various
immune cytokines by ELISA in the serum collected from each
mouse. IL-2 increased significantly in the systemic circulation from
2 days after i.v. KITENIN siRNA injection, and this effect was
observed until 4 days (Fig. 3B). In addition, IFN-g increased
significantly from days 2 to 5 after injection (Fig. 3C). In contrast,
no significant differences were found in IL-1, IL-4, IL-5, and IL-6
levels between the experimental groups (data not shown).
Accumulation of immune T cells was observed in the KITENIN
siRNA injected regressed tumor tissues. CD4+ helper T cells
(Fig. 4E) and CD8+ cytotoxic T cells (Fig. 4F) were increased in
the regressed tumor tissues from 2 days and peaked at 4 days
(Fig. 4I and M, J and N) after single injection. In addition, apoptotic
cells containing segmented nuclei were found around the CD8+ T
cells (Fig. 4N). These results indicate that the effects of a single i.v.
KITENIN siRNA injection on the immune response and tumor
growth persisted for about 4 days. In addition, KITENIN siRNA was
effective at promoting tumor cell destruction accompanied by
extensive necrosis and apoptosis, whereas the integrity of the
tumors was completely preserved following treatment with control
vector. Thus, in vivo silencing of KITENIN is effective in stimulating
T1-type antitumor response in vivo , as shown by increases in serum
immune cytokines, such as IL-2 and IFN-g levels. It also increases
cytotoxic T-cell infiltration in the tumor tissue and thereby delays
tumor growth. These results indicate a positive functional
correlation between suppressed KITENIN levels in tumor tissues
and antitumor T-cell responses in vivo .
Semiweekly injections of KITENIN short interfering RNA
enhance its antitumor effect. Either 50 Ag of both KITENIN
siRNA S2 and S5, or 100 Ag of pSUPER vector mixed with FuGENE
6, was given i.v. for 4 weeks in BALB/c mice with two injections per
week started at 1 week after the injection of CT-26 cells. We
compared the tumor volumes of semiweekly injection group with
those of vector alone or weekly injection group. Compared with the
control group, in vivo tumor progression was markedly delayed
after the 4th injection of KITENIN siRNA, which was corresponding
2 weeks from the first injection (Fig. 5A). Notably, almost complete
Figure 1. A pSUPER vector–based suppression of KITENIN expression in cultured cells and in vivo distribution and inhibition of KITENIN. A, silencing of KITENIN
expression in 293 (top ) or KM1214 (bottom ) cells using pSUPER vectors producing siRNA to KITENIN (pSUPER-KITENIN). The indicated pSUPER-KITENIN (S1-S5)
was transiently transfected into 293 or KM1214 cells for 48 hours. KITENIN expression (arrow ) was markedly decreased in the S2 (KIT siRNA S2)– or S5
(KIT siRNA S5)–transfected cells. In vitro translated KITENIN (KITENINV5, f65 kDa) was used as a positive control. Actin was used as an evidence for the protein
loading control. B, efficient silencing of KITENIN in the CT-26 cells using pSUPER-KITENIN. KITENIN (arrow ) was nearly absent in the CT-26 cells stably cotransfected
with KIT siRNA S2 and S5. C, tissue distribution of green fluorescent protein at 3 days after i.v. injection of KIT siRNA S2 or S5. Representative images (n = 4;
top , low-power field; bottom , high-power field) in mouse liver, lung, and spleen, which showed substantial amount of the fluorescence and a marked uptake was
localized around the blood vessels. D and E, in vivo inhibition of KITENIN expression by i.v. pSUPER-KITENIN injection. Mice were i.v. injected with both KIT siRNA S2
and S5, and total RNAs (D) or proteins (E) were isolated from liver, lung, spleen, and kidney following 3 days, 1, 2, 3, and 4 weeks after injection. The decreased
KITENIN mRNAs peaked at 2 weeks (D), whereas decreased proteins persisted until 3 weeks (E ).
Cancer Research
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regression of established tumor with removal of crust and new
epithelial tissue in the tumor area was observed in two of six mice.
Whereas, the entire necrotic tumor mass disappeared from the
back skin in two of six mice, and a part of the necrotic tumor mass
sloughed from the back in the two remaining mice after the fourth
injection of KITENIN siRNA (Fig. 5B). Moreover, after 2 weeks,
progression of tumor was more suppressed than that of the group
receiving four weekly KITENIN siRNA injections (Fig. 5A). However,
the tumor grew very slowly again in all mice, despite further
KITENIN siRNA injections. After the eighth injection of KITENIN
siRNA, all mice had regrowing tumor mass, but it is still smaller
than that of control group (Fig. 5C). This result suggests that the
proliferation of tumor cells overwhelms the ability of the host
immune response to suppress the tumor growth, or effects of
KITENIN siRNA were down-regulated after repeated injections.
90K protein interacts with KITENIN and suppressed
KITENIN in the tumor cells augments 90K release. To examine
how KITENIN siRNA causes tumor regression and inhibition of
metastasis, we searched for proteins capable of association with
KITENIN by a yeast two-hybrid screen using the full-length of
KITENIN as bait. By screening a mouse testis cDNA library, we
isolated and sequenced several positive clones that revealed
specific interaction with KITENIN. Two cDNA clones were
identified as 90K and PKCI proteins.
Figure 2. Effect of in vivo KITENIN gene
silencing on progression of established
tumor, survival, and distant metastases in
experimental colon cancer of mice.
A, effect of i.v. pSUPER-KITENIN injection
on in vivo progression of experimental
tumor. A mixture of pSUPER-KITENIN
(S2 and S5) with FuGENE 6 was given into
the tail vein of mice weekly for 1 month at
1 week before, simultaneously, and 1 week
after the injection of CT-26 cells (arrows ).
Points, mean tumor volumes. B, effect of
i.v. pSUPER-KITENIN injection done after
tumor formation on progression of
experimental tumor. pSUPER-KITENIN
was given weekly five times starting at
1 and 2 weeks after the injection of CT-26
cells (arrows ) in which the tumor was
just and already formed, respectively.
C, survival curves of tumor-bearing mice
given pSUPER-KITENIN or vector alone.
D, pSUPER-KITENIN delivery suppresses
distant metastases in the mouse colon
cancer model. After 6 weeks, liver and lung
metastases were detected in all mice in
control group (n = 20, top, arrows ),
whereas liver or lung was still intact in
the mice (n = 12 of 13, bottom ) with
pSUPER-KITENIN. Bar, 50 Am.
Figure 3. Effects of a single i.v. pSUPER-
KITENIN injection on growth of established
tumor, and serum cytokine levels of
syngeneic mice. A, duration of regression
effect on the established tumor by a single
pSUPER-KITENIN injection. At 2 days after
injection, tumor size was decreased and
crust formation was observed, but tumor
growth started again after 5 days. One of
three representative experiments. B and C,
in vivo silencing of KITENIN increases
serum immune cytokines. From days 1 to 6
after injection, blood was pooled from two
mice after measuring tumor volume, and
amounts of various cytokines were
measured. B, serum IL-2 was higher from
2 days after pSUPER-KITENIN than that of
control group and this effect was observed
until 5 days. C, IFN-g increased from
days 2 to 5 after pSUPER-KITENIN more
than that of control group. Columns, means
(n = 6) for each ELISA; bars, FSE.
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To confirm the interaction of KITENIN with 90K in mammalian
cells, we did an immunoprecipitation assay using CT-26 cell lines.
Cell lysate and in vitro translated 90K (90KV5, 90K-V5 fusion
protein) were reacted with anti-V5 (Fig. 6A) or anti-KITENIN
antibody (Fig. 6B) and blotted with anti-KITENIN or anti-V5
antibody. KITENIN protein (Fig. 6A) and 90K protein was observed
(Fig. 6B). We also confirmed that 90K protein interacts with the
extracellular region of KITENIN with pull-down assay (Fig. 6C). To
analyze the role of the interaction between KITENIN and 90K on a
functional in vivo antitumor response, stably 90K-expressing CT-26
cell lines were established. CT-26 cells were stably transfected with
pcDNA-90K cDNA (CT-26/90K), and also CT-26/90K cells were
stably transfected with pREP4-antisense-KITENIN cDNA (CT-26/
90K/antisense KITENIN). 90K expression in selected clones was
then analyzed by RT-PCR analysis, because 90K protein is secreted
into extracellular space with glycosylated form and antibody
against human 90K did not detect the mouse protein (data not
shown). To examine whether there are associations between 90K
levels and KITENIN expression, we measured the quantity of 90K
secreted in supernatants of CT-26/90K and CT-26/90K/antisense
KITENIN cells. Supernatants were obtained by centrifugation of
culture medium collected from CT-26/90K or CT-26/90K/antisense
KITENIN cells 2 days after passage. The 90K band (f90 kDa) was
detected in the culture medium of CT-26/90K cells but not from
cell extracts (Fig. 6D) indicating that newly synthesized 90KV5 was
secreted into the extracellular space. The secreted 90K was
markedly increased in the CT-26/90K/antisense KITENIN cells
compared with CT-26/90K cells, indicating that 90K secretion is
increased by antisense KITENIN. In addition, endogenous 90K
secretion was increased significantly in the culture medium of 24
and 48 hours from stably pSUPER-KITENIN S5 transfected KM1214
cells compared with KM1214/vector cells (Fig. 6E). These results
indicate that reduced KITENIN permits 90K secretion from tumor
cells.
Coculture with 90K secreting tumor cells increases inter-
leukin-1 and interleukin-6 secretions in Raw 264.7 cells. To
investigate whether 90K protein in the culture medium is also
derived from immune T cells as well as nonimmune tumor cells,
RT-PCR analysis of 90K mRNA was done in the stably antisense
KITENIN–transfected Jurkat cells. KITENIN expression decreased
as a result of stable antisense KITENIN construct transfection;
however, 90K expression also decreased at the same time (Fig. 7A).
In addition, 90K was measured in the conditioned medium from
stably antisense KITENIN–transfected Jurkat cells. Consistent with
Figure 5. Antitumor effects of pSUPER-KITENIN were enhanced by increasing
injection frequency. pSUPER-KITENIN (S2 and S5) or control vector was given
twice weekly at 1 week after the injection of CT-26 cells (an arrow ). Points,
mean tumor volumes. A, in vivo progression of established tumor was markedly
suppressed after the fourth injection of pSUPER-KITENIN compared with that of
the vector group. B, after the fourth injection of pSUPER-KITENIN, the nearly
complete regression of established tumor with removed crust in the tumor
area was observed in two of six mice. C, after the eighth injection of
pSUPER-KITENIN, all mice had regrowing tumor mass, which is still smaller
compared with that of vector group.
Figure 4. Sequential T-cell infiltration in the
established tumor tissue of syngeneic mice following a
single i.v. pSUPER-KITENIN injection. Representative
images (A-J , low-power field; K-N , high-power field)
of CD4+ (A, C, E, G, I, K , and M ) and CD8+ (B, D, F, H,
J, L , and N) T cells (n = 3). A mouse spleen specimen
was included as a positive control for CD4+ (A ) and
CD8+ (B ) T cells. C-J, accumulation of CD4+ and CD8+
T cells in the regressed tumor tissues started from
2 days (E and F ), peaked at 4 days (I and J ), and was
maintained until 7 days after pSUPER-KITENIN
injection compared with those at 4 days after vector
injection (C and D ). In high-power field (K-N ), CD4+
helper (M ), and CD8+ cytotoxic (N ) T cells were
increased in the pSUPER-KITENIN delivered
regressed tumor tissues at 4 days compared with those
of vector injection (K and L). In addition, apoptotic cells
containing segmented nuclei (arrows ) were found
around the CD8+ T cells (N ). Bar, 50 Am.
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result of the RT-PCR analysis, secretion of endogenous 90K
decreased in the culture medium (Fig. 7B). These results indicate
that 90K protein in the culture medium is derived from nonimmune
tumor cells.
To examine whether secreted 90K could augment the immune
response, Raw 264.7 cells were double cultured with CT-26/90K or
CT-26/90K/antisense KITENIN cells using a Transwell apparatus.
After 48 hours, supernatants were harvested and assayed for the
accessory cell–derived cytokines, IL-1, IL-2, IL-4, IL-5, IL-6, and
IFN-g. Double culture of accessory cells with CT-26/90K/antisense
KITENIN cells revealed that the production of IL-1 (Fig. 7C) and
IL-6 (Fig. 7D) was increased by 2- and 4-fold compared with that
of double culture with CT-26/p cells. In contrast, no significant
differences were found in IL-2, IL-4, IL-5, and IFN-g levels
between double cultured cells (data not shown). To examine
whether the purified 90K protein will also show the similar effects
on Raw 264.7 cells, concentration of IL-1 and IL-6 were measured
in the cultured medium harvested at 24 hours after adding graded
amounts of purified 90K. The amounts of IL-1 (Fig. 7E) and IL-6
(Fig. 7F) in medium were increased by dose-dependent manner
by 90K protein. These results confirmed that suppression of
KITENIN induced 90K secretion from CT-26 tumor cells, and
secreted 90K protein stimulated accessory cells to increase the
secretion of IL-1 and IL-6. In addition, this result of immune
cytokine secretions was parallel with that of 90K secretion
from genetically engineered CT-26 cells (Fig. 6B). However, IL-1
(Fig. 7C) and IL-6 (Fig. 7D) were increased more in the double
culture with CT-26/p cells than those of Raw 264.7 cells only,
suggesting that the ability to stimulate the cytokine secretion
could not be attributed solely to the 90K protein itself. None-
theless, we conclude that the culture of accessory cells with 90K
protein from tumor cells is sufficient to stimulate the secretion of
IL-1 and IL-6.
Combination of 90K expression and KITENIN suppression
reduces tumor growth and metastasis in vivo . To investigate
whether overexpression of 90K affects colon tumor progression, we
established cell lines overexpressing 90K with or without express-
ing antisense KITENIN cDNAs. RT-PCR analysis showed that 90K
Figure 6. Direct interaction of 90K with KITENIN and the effect of antisense KITENIN on 90K release. A and B, immunoprecipitation (IP ) analysis of the 90K in the
CT-26 cells. Cell lysate mixed with in vitro translated 90KV5 was incubated with protein A/G agarose beads and anti-V5 (A ) or anti-KITENIN antibody (B ). The
immunoprecipitates were resolved by SDS-PAGE and blotted with anti-KITENIN or anti-V5 antibody. Arrow, f65-kDa KITENIN (A) or in vitro translated f65-kDa
90KV5 protein (B ). C, identification of KITENIN region required for interaction with 90K. Indicated region of V5-tagged KITENIN protein was purified using in vitro
translation system and mixed with purified His-90K protein. These mixtures were incubated with protein A/G agarose beads and anti-V5 antibody or control mouse IgG.
The immunoprecipitates were blotted with anti-90K antibody. The presence of interactions between 90K and roughly whole region of KITENIN devoid of partial
NH2-terminal region (ND78 Kit-V5), and extracellular region of KITENIN (Extra-Kit-V5), and roughly whole region of KITENIN devoid of COOH-terminal region (1-237 aa
Kit-V5) indicate that extracellular portion of KITENIN interacts with 90K. N-cyto Kit-V5 is full NH2-terminal cytoplasmic region; 238-524 aa Kit-V5 is full COOH-terminal
cytoplasmic portion. D, immunoblot analysis of cell lysate and conditioned medium harvested from stably 90K-transfected CT-26 cells. Each cell lysate was
immunoblotted with anti-V5 antibody. In addition, culture medium (sup ) from each cell was immunoprecipitated with anti-V5 antibody and immunoblotted with anti-V5
antibody. Jurkat cells were included as a negative control for immunoprecipitation. Note that the molecular size of in vitro translated 90K (arrow ) and endogenous
precursor (arrowhead , in CT-26/AS-KITENIN/90K cells) of the glycosylated 90K protein are f65 and f76 kDa, respectively. This 76-kDa protein is not detected in
the culture medium. E, increased endogenous 90K secretion in the culture medium from stably pSUPER-KITENIN S5–transfected KM1214 cells. **, P < 0.01 and
***, P < 0.001 (significant difference in 90K secretion between groups).
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increased in the CT-26/90K and CT-26/antisense KITENIN/90K
cells (Fig. 8A). To examine the effects of 90K expression with or
without suppressed KITENIN on in vivo tumor growth, CT-26/p,
CT-26/90K, CT-26/antisense KITENIN, and CT-26/90K/antisense
KITENIN cells were injected s.c. in syngeneic mice at a density of
1  106 cells. All of the mice inoculated with above CT-26 cells
formed tumors; the mice inoculated with CT-26/90K/antisense
KITENIN cells showed the most delayed tumor growth among
them (Fig. 8B). However, tumor sizes obtained from CT-26/90K
cells were similar to those from CT-26/p cells, indicating that
released 90K from CT-26/90K cells was not sufficient to suppress
tumor growth. In addition, the mice inoculated with CT-26/90K
cells (Fig. 8C, middle columns) did exhibit lung and liver metastases
at 4 and 6 weeks after injection, respectively, just like the mice with
CT-26/p cells (Fig. 8C, top columns), indicating that released
90K alone does not inhibit metastasis. However, there were no
metastatic foci in the lung and liver of the mice with CT-26/
antisense KITENIN/90K cells (Fig. 8C, bottom columns). Therefore,
we confirmed that the association between 90K protein and
KITENIN is responsible for immune augmentation and thereby for
the regression of established tumor observed but not for the
metastasis.
Figure 7. The 90K protein in the culture
medium is derived from nonimmune
tumor cells and stimulates the secretion
of cytokines from accessory cells.
A, RT-PCR analyses of KITENIN and
90K mRNAs in stably antisense
KITENIN–transfected Jurkat cells.
B, measurement of 90K protein in the
conditioned medium from stably antisense
KITENIN–transfected Jurkat cells. C and
D, measurement of cytokines in the
double-cultured accessory cells/tumor
cells. The amounts of IL-1 (C ) and IL-6
(D ) in double-cultured medium of Raw
264.7 cells and CT-26/AS-KITENIN/90K
cells were increased significantly more
than those of Raw 264.7 cells and CT-26/p
cells or Raw 264.7 cells and CT-26/90K
cells. Columns, means (n = 3) for each
ELISA; bars, FSE. *, P < 0.05 (significant
difference in IL-1 or IL-6 secretion between
groups). E and F, measurement of IL-1
or IL-6 in the accessory cells by treatment
of purified 90K protein from supernatant
of CT-26/90K/AS-KITENIN cells. The
amounts of IL-1 (E) and IL-6 (F ) in the
cultured medium of Raw 264.7 cells were
increased after adding graded amounts
(AL) of 90K. Columns, means (n = 3) for
each ELISA; bars, FSE.
Figure 8. Effect of 90K expression in
addition to suppressed KITENIN on in vivo
tumor progression and metastases.
A, establishment of cells expressing 90K
with or without AS-KITENIN cDNAs.
RT-PCR analysis showed that 90K
expression (arrow) was higher in the
CT-26/90K and CT-26/AS-KITENIN/90K
cells than corresponding cells. B, effect of
90K expression with or without reduced
KITENIN on in vivo tumor progression.
Tumor growth was induced by s.c.
injection of CT-26/p, CT-26/90K,
CT-26/AS-KITENIN, or CT-26/AS-
KITENIN/90K cells in BALB/c mice
(n = 8 or 11 per group). Points, mean
tumor volumes. C, expression of 90K alone
did not influence the distant metastases
in mouse tumor model. Four weeks after
cell injection (n = 12 per group), lung
metastasis was detected in mice injected
with CT-26/parent cells (top left, arrows )
and with CT-26/90K cells (middle left) but
not with CT-26/AS-KITENIN/90K cells
(bottom left ). Six weeks after injection, liver
and lung metastases were still not detected
in mice injected with CT-26/AS-KITENIN/
90K cells (bottom right ) but with CT-26/90K
cells (middle right ). Bar, 50 Am.
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KITENIN interacts with protein kinase C inhibitor, and
protein kinase C inhibitor increases invasiveness of CT-26
cells in vitro . For immunoprecipitation to confirm the interaction
of KITENIN with PKCI, CT-26 cell lysate or CT-26 cell lysate mixed
with in vitro translated PKCI was reacted with anti-KITENIN
(Fig. 9A) or anti-V5 antibody (Fig. 9B) and blotted with anti-PKCI
or anti-KITENIN antibody. PKCI protein or KITENIN protein
appeared as a f13-kDa (Fig. 9A) or a f65-kDa band (Fig. 9B),
indicating an association of PKCI with KITENIN in mammalian
cells. In subsequent pull-down assay, we confirmed that the
COOH-terminal region of KITENIN interacts with PKCI protein
(Fig. 9C).
The forced expression of KITENIN in the CT-26/p cells resulted
in the increased expression of PKCI, whereas the expression of
PKCI protein was reduced in the CT-26/antisense KITENIN cells
compared with CT-26/vector cells (Fig. 9D). This result indicates
that KITENIN directly or indirectly causes the increased expression
of PKCI. Transwell invasion assays were used to investigate
whether the PKCI affects the in vitro invasive potential of
CT-26 cells, as KITENIN does. Cell motility was measured using
fibronectin as a chemotactic factor. We established CT-26 cell lines
overexpressing PKCI or stably expressing antisense PKCI cDNAs.
Western blot analysis showed that PKCI expression was increased
in the CT-26/PKCI cells, whereas reduced in the CT-26/antisense
PKCI cells compared with CT-26/vector cells (Fig. 9E). Compared
with CT-26/vector cells, CT-26/PKCI cells showed significantly
increased in vitro motility and invasive potential induced by
fibronectin, whereas significantly decreased in CT-26/antisense
PKCI cells (Fig. 9F). This result indicates that PKCI is involved in
the invasiveness of CT-26 cells into extracellular matrix.
Ablation of KITENIN induces a distorted actin phenotype.
Previously, we found that the transfection of antisense KITENIN
cDNA into CT-26/p or CT-26/KAI1 cells was associated with
development of a longer process than on CT-26/p or CT-26/
KITENIN cells (11, 14). Thus, we speculated that the morphologic
changes caused by reduced KITENIN might be caused by changes
in the cytoskeleton. Therefore, we examined the cellular morpho-
logy of CT-26/antisense KITENIN cells by confocal microscopy.
Western blot analysis showed that KITENIN expression was nearly
absent in the CT-26/antisense KITENIN cells (Fig. 10A). In CT-26/
vector cells, actin was arranged in a radial pattern from the nucleus
to the periphery of the cytoplasm (Fig. 10B) and showed a
continuous filamentous shape (Fig. 10C). However, in the antisense
KITENIN–transfected CT-26 cells, the arrangement of filamentous
Figure 9. Direct interaction of PKCI with KITENIN and PKCI involvement in the invasiveness of tumor cells. A and B, immunoprecipitation (IP ) analysis of PKCI that
interacted with KITENIN. CT-26 cell lysate was incubated with protein A/G agarose beads and anti-KITENIN antibody (A) or with PKCIV5 protein, protein A/G agarose
beads, and anti-V5 antibody (B ) and blotted with anti-PKCI or anti-KITENIN antibody. Arrow, f15-kDa PKCI (A ) or the f65-kDa KITENIN (B ). C, identification of
KITENIN region required for interaction with PKCI. Indicated region of V5-tagged KITENIN protein was mixed with purified HA-PKCI protein. These mixtures were
incubated with protein A/G agarose beads and anti-V5 antibody or control mouse IgG. The immunoprecipitates were blotted with anti-PKCI antibody. Arrow, f23-kDa
HA-PKCI protein. The presence of strong interaction between PKCI and 238-524 Kit-V5 indicates that PKCI interacts with COOH-terminal cytoplasmic region of
KITENIN. D, relationship between expression levels of KITENIN and PKCI. The expression level of PKCI (arrows ) was examined in KITENIN-expressing CT-26 cell
lines. E, establishment of CT-26 cell lines expressing changed PKCI. F, effect of PKCI expression on in vitro invasiveness of colon cancer cells. Compared with
CT-26/vector cells, CT-26/PKCI cells had greater invasive potential induced by fibronectin, whereas lesser in CT-26/AS-PKCI cells (top ). Columns, mean of the mean
number of migrated cells per field; bars, FSE (bottom ). *, significant difference in cell migration among the CT-26 cell groups.
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actin was disrupted and distorted (Fig. 10D and E). Thus,
decreased KITENIN seems to be related to the distorted actin,
which may partially explain the absence of distant metastasis
observed in the mice injected with CT-26/antisense KITENIN cells.
Decreased PKCI also disrupts actin fiber arrangement.
Because decreased KITENIN was related to the expression of
distorted actin, we also examined the cellular morphology of
CT-26/antisense PKCI cells (Fig. 9E) by confocal microscopy.
Compared with CT-26/vector cells, the actin fiber arrangement was
markedly disrupted and distorted after antisense PKCI transfection
(Fig. 10F and G), just like in CT-26/antisense KITENIN cells.
Discussion
KITENIN is expressed by many different tumors, and its
expression correlates with the acquisition of metastatic pheno-
types (11). In this study, we observed that weekly or semiweekly
injection of pSUPER-KITENIN for 1 month markedly inhibited the
growth of established tumors and suppressed the distant
metastases to liver and lung. Secretion of 90K, a KITENIN-
interacting protein, was higher in culture medium from the
antisense KITENIN cDNA–transfected CT-26 and KITENIN siRNA–
transfected KM1214 colon cancer cells but not from the immune
Jurkat/antisense KITENIN cells. However, normal tumor growth
was observed during 2 weeks after injection of CT-26 cells in mice
in which i.v. KITENIN siRNA delivery was started at 1 week before
the tumor challenge, whereas tumor size had regressed after the
fourth injection given at 2 weeks after the tumor challenge. These
results suggested that 90K was released from established growing
tumor tissue by KITENIN siRNA and might be associated with
antitumor action of in vivo KITENIN ablation.
The 90K tumor-derived glycoprotein has been shown to have
positive effects on the generation of cytotoxic effector cells from
human PBMC, such as natural killer cells and lymphokine-activated
killer cells. 90K is a soluble costimulatory molecule that acts at
the level of the accessory cell, indirectly supporting T-cell activation
through expression of adhesion molecules as well as on cytokine
production (9). It binds to h1-integrin, collagen, and fibronectin
as well as galectin-1, galectin-3, and galectin-7 (7, 16–18). Based
on these reports, it seems that the released 90K protein from
extracellular portion of KITENIN following KITENIN siRNA
injection could be part of the host defense mechanisms facilitating
the elimination of established growing tumors. To determine
whether local production of 90K from CT-26 tumor cells causes
immune reactions, we have examined the effects of 90K on cytokine
production in Raw 264.7 cells, a mouse macrophage cell line.
Coculture of Raw 264.7 cells with CT-26/antisense KITENIN/90K
cells or treatment of Raw 264.7 cells with purified 90K protein
revealed increased secretion of IL-1 and IL-6, which was also
observed in a previous report (9). IL-1 supports the antigen-driven
activation of T cells (19) and the production of lymphokines such as
IL-9 (20). IL-6 exhibits a number of effects on T-cell activation,
including stimulation of thymocyte proliferation, enhancement of
cytotoxic T-cell differentiation in mixed lymphocyte reactions, and
T-cell activation in conjunction with TCR cross-linking or mitogen
stimulation (21). Increased secretion of proinflammatory cytokines
such as IL-1 and IL-6 by 90K after KITENIN siRNA could result in a
greater degree of infiltrating activated T-helper and effector cells.
Indeed, we observed increased secretion of IL-2 and IFN-g in the
peripheral blood, and infiltration of CD8+ as well as CD4+ T cells in
the regressed tumor tissues from mice injected with pSUPER-
KITENIN.
In contrast, our results suggest that, after injection of KITENIN
siRNA into syngeneic mice, nonimmune tumor cells or normal cells
that express KITENIN (7) may initiate to increase the T-cell effector
functions by secretion of 90K through ablating KITENIN expres-
sion, and that this mechanism may contribute to the generation of
a tumor-specific T1-type response and thereby may serve as
effective inhibitors to the spread of tumors within the host.
Recently, rat 90K was reported to increase MHC class I, and both
90K and MHC class I were coordinately increased by introducing
double-stranded polynucleotides into FRTL-5 rat thyroid cells,
which support a role of 90K in immune self defense mechanisms of
nonimmune cells (22).
However, 90K also possess the negative influence on the prognosis
of various cancers (10). Several studies have shown that high 90K
levels are associated with a poor prognosis and the presence of
metastasis in breast cancer (23) and non–small cell lung cancer
(24). It seemed that the negative influence of 90K on prognosis
was related to binding with galectins, and that malignant cell
transformation and cancer progression are associated with
increased expression of galectin-1, galectin-3, and 90K (25). To
explain these contradictory observations, it should be examined
whether 90K protein is also produced by host cells in response to
tumor progression and this endogenous 90K acts as ligands to tumor
cells by binding to extracellular portion of KITENIN rather than acts
to accessory cells, because the different origin of the protein may in
turn have a differential influence on the course of various cancers.
The final result of an effective antitumor response can be
determined by a delicate interaction between activating and
Figure 10. Effects of antisense KITENIN and antisense PKCI cDNA transfection
on microfilament arrangement. A, establishment of cell lines expressing
AS-KITENIN. KITENIN (arrow) was nearly absent in the CT-26/AS-KITENIN
cells. B-G, actin in CT-26 cells was visualized. Control vector–transfected CT-26
cells (B and C ), anti-KITENIN cDNA–transfected cells (D and E ), and anti-PKCI
cDNA–transfected cells (F and G). Note that the absence of KITENIN
expression disturbs the arrangement of the actin (D ) and causes distortion (E),
and that decreased PKCI expression also disturbs the arrangement of the actin
(F ) and causes distortion (G), just as in the CT-26/AS-KITENIN cells. Bars,
30 Am (B, D , and F ) and 75 Am (C, E , and G).
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inhibitory regulatory pathways and that removal of inhibitory
signals may be a particularly useful adjunct to other anticancer
therapies (26). Interestingly, inhibition of cell proliferation was
observed after transient transfection of KITENIN into Raw or Jurkat
cells, which express a very low KITENIN level (data not shown).
Thus, our results suggest that KITENIN may act as one of the
negative regulators of T-cell activation and survival and confer
immune privilege to tumor cells, whereas blockade of KITENIN
in vivo stimulates the generation of tumor-specific type 1 T cell–
mediated immune responses in syngeneic mice and thereby
suppresses tumor cell proliferation. In addition, the mice
inoculated with CT-26/90K/antisense KITENIN cells showed more
delayed tumor growth than the mice with CT-26/antisense
KITENIN, confirming that 90K protein is really responsible for
immune augmentation by KITENIN siRNA injection. Therefore, our
data provided evidences of anti-KITENIN/90K-mediated immunos-
timulation as a novel mechanism of tumor regression and indicated
that ablation of KITENIN in the growing tumor cells by systemic
delivery of anti-KITENIN siRNA has strong therapeutic potential to
shift the balance in favor of an efficient T cell–mediated antitumor
immune response.
In this study, we showed that rearrangement of actin and
increased in vitro invasiveness to fibronectin are associated with
KITENIN and PKCI. Thus, PKCI seems to be involved in the
metastasis enhancing property of KITENIN. The PKCI protein was
originally identified by its ability to inhibit the in vitro kinase
activity of bovine brain PKC (27). However, previous study suggests
that in vivo the ubiquitously expressed PKCI protein, although
localized mainly in the nucleus, does not function as an inhibitor
of PKC but rather acts as an enzyme in an unidentified pathway
(28) or a regulator of gene transcription (29–31). Recently, it was
reported that PKCI/ mouse embryo fibroblasts display sponta-
neous immortalization during serial passage (32). However, it is
unknown in this study how the interaction of KITENIN, membrane
protein, and PKCI, the major function of which may reside in the
nucleus, is related to increased invasiveness of tumor cells. This
study indicates that released 90K alone is not involved in the
inhibition of the distant metastasis by KITENIN ablation. Thus, we
suppose that other signal transduction pathways should exist to
link KITENIN with cytoskeletal proteins as well as balancing the
KAI1’s action by KITENIN, and that KITENIN activates this
signaling pathway involving PKCI. These interactions may result in
the formation of multimeric protein complexes that influence
downstream signaling effectors involved in cell motility and
invasion.
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